Stocks in play: IntelGenx Corp.
Announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease patients in the Phase 2 clinical trial. IntelGenx Corp. shares T.IGX are trading unchanged at $0.23.
Read:
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates
Harnessing AI's $4.4 Trillion Potential Reshapes the Tech Industry Landscape
Critical Push for US Domestic Nickel Needed to Halt Total Reliance on Questionable Foreign Imports
How Argentina’s New Power Moves Look to Lure Even More Lithium Interest Towards the Country
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer